- Home
- ZVSA vs CETX Comparison
ZVSA vs CETX Comparison
Compare ZVSA & CETX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZVSA
- CETX
- Stock Information
- Founded
- ZVSA 2014
- CETX 1998
- Country
- ZVSA United States
- CETX United States
- Employees
- ZVSA N/A
- CETX N/A
- Industry
- ZVSA Biotechnology: Pharmaceutical Preparations
- CETX EDP Services
- Sector
- ZVSA Health Care
- CETX Technology
- Exchange
- ZVSA Nasdaq
- CETX Nasdaq
- Market Cap
- ZVSA 2.5M
- CETX 2.3M
- IPO Year
- ZVSA N/A
- CETX 1998
- Fundamental
- Price
- ZVSA $1.10
- CETX $3.00
- Analyst Decision
- ZVSA Strong Buy
- CETX
- Analyst Count
- ZVSA 1
- CETX 0
- Target Price
- ZVSA $240.00
- CETX N/A
- AVG Volume (30 Days)
- ZVSA 243.8K
- CETX 912.3K
- Earning Date
- ZVSA 11-14-2024
- CETX 02-10-2025
- Dividend Yield
- ZVSA N/A
- CETX N/A
- EPS Growth
- ZVSA N/A
- CETX N/A
- EPS
- ZVSA N/A
- CETX N/A
- Revenue
- ZVSA N/A
- CETX $65,318,942.00
- Revenue This Year
- ZVSA N/A
- CETX $17.30
- Revenue Next Year
- ZVSA N/A
- CETX $15.00
- P/E Ratio
- ZVSA N/A
- CETX N/A
- Revenue Growth
- ZVSA N/A
- CETX 19.78
- 52 Week Low
- ZVSA $0.98
- CETX $2.71
- 52 Week High
- ZVSA $25.00
- CETX $13,629.00
- Technical
- Relative Strength Index (RSI)
- ZVSA 41.83
- CETX 18.18
- Support Level
- ZVSA $0.99
- CETX $3.10
- Resistance Level
- ZVSA $1.20
- CETX $3.54
- Average True Range (ATR)
- ZVSA 0.08
- CETX 0.35
- MACD
- ZVSA 0.04
- CETX 2.30
- Stochastic Oscillator
- ZVSA 54.55
- CETX 28.08
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
About CETX Cemtrex Inc.
Cemtrex Inc is a multi-industry technology company. It has expanded in a range of sectors, including smart technologies, virtual and augmented realities, industrial solutions, and intelligent security system. The company's operating segment includes the Security segment, Industrial Services segment and the Corporate segment. It generates maximum revenue from the Security segment. It geographically operates in USA, UK and India wherein maximum revenue is generated in USA.